Working… Menu

Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer (CONDOR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03739684
Recruitment Status : Completed
First Posted : November 14, 2018
Last Update Posted : April 23, 2021
Information provided by (Responsible Party):
Progenics Pharmaceuticals, Inc.

Brief Summary:
This study evaluates the diagnostic performance and safety of 18F-DCFPyL (PyL) PET/CT imaging in patients with suspected recurrence of prostate cancer who have negative or equivocal findings on conventional imaging.

Condition or disease Intervention/treatment Phase
Prostate Cancer Prostate Adenocarcinoma Prostate Cancer Recurrent Prostate Cancer Metastatic Drug: 18F-DCFPyL Diagnostic Test: PET/CT Imaging Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 208 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: A Phase 3, Multi-Center, Open-Label Study to Assess the Diagnostic Performance and Clinical Impact of 18F-DCFPyL PET/CT Imaging Results in Men With Suspected Recurrence of Prostate Cancer
Actual Study Start Date : November 27, 2018
Actual Primary Completion Date : August 29, 2019
Actual Study Completion Date : August 29, 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 18F-DCFPyL Injection
9 mCi (333 MBq) IV injection of 18F-DCFPyL
Drug: 18F-DCFPyL
A single dose of 9 mCi (333 MBq) IV injection of 18F-DCFPyL
Other Name: PyL

Diagnostic Test: PET/CT Imaging
PET/CT imaging will be acquired 1-2 hours post-PyL injection

Primary Outcome Measures :
  1. Correct Localization Rate (CLR), defined as percentage of subjects with a one-to-one correspondence between localization of at least one lesion identified on 18F-DCFPyL PET/CT imaging and the composite truth standard. [ Time Frame: Within 60 days following PyL PET/CT imaging. ]
    Within 60 days following PyL PET/CT imaging, either biopsy/surgery, conventional imaging, or locoregional radiation therapy of the PyL-suspected lesion(s) will be performed.

Secondary Outcome Measures :
  1. Percentage of subjects with a change in intended prostate cancer treatment plans due to 18F-DCFPyL PET/CT imaging results. [ Time Frame: Pre-PyL imaging and within 60 days following PyL imaging. ]
    The change in intended prostate cancer treatment plan will be based on Medical Management Questionnaires completed prior to and after PyL PET/CT imaging.

  2. Incidence of treatment-emergent adverse events (TEAEs) from time of 18F-DCFPyL dosing up to 7 (+/- 3 ) days after 18F-DCFPyL dosing. [ Time Frame: From time of 18F-DCFPyl dosing up to 7 (+/- 3) days after dosing ]
    The incidence and percentage of participants reporting TEAEs will be summarized by MedDRA SOC and Preferred Term. Severity will be rated using the CTCAE 5-point scale.

  3. The change from baseline to post 18F-DCFPyl dosing in blood pressure. [ Time Frame: Prior to receiving the 18F-DCFPyL dose and within 60 to 120 minutes after dosing ]
    The recorded values and their respective changes from the pre-dose values will be summarized using descriptive statistics.

  4. The change from baseline to post 18F-DCFPyL dosing in heart rate. [ Time Frame: Prior to receiving the 18F-DCFPyL dose and within 60 to 120 minutes after dosing. ]
    The recorded values and their respective changes from the pre-dose values will be summarized using descriptive statistics.

  5. Collection of concomitant medications and medical procedures. [ Time Frame: From the time of 18F-DCFPyL dosing to completion of the follow-up visit. ]
    Medications will be coded using the WHO drug dictionary. Medications will be summarized by ATC level 4 category and preferred term, and presented as number and percentage of participants. Procedures will be coded using the same version of MedDRA as for medical history. Medical procedures will be displayed as a listing by participant.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Only males subjects will be enrolled in this study.
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male >/= 18 years of age
  • Histopathologically confirmed prostate adenocarcinoma per original diagnosis, with subsequent definitive therapy
  • Suspected recurrence of prostate cancer based on rising PSA after definitive therapy on the basis of:

    1. Post-radical prostatectomy: Detectable or rising PSA that is ≥ 0.2 ng/mL with a confirmatory PSA ≥ 0.2 ng/mL (American Urological Association [AUA]); or
    2. Post-radiation therapy, cryotherapy, or brachytherapy: Increase in PSA level that is elevated by ≥ 2 ng/mL above the nadir (American Society for Therapeutic Radiology and Oncology [ASTRO]-Phoenix)
  • Negative or equivocal findings for prostate cancer on conventional imaging performed as part of standard of care workup within 60 days prior to Day 1
  • Life expectancy ≥6 months as determined by the investigator
  • Able and willing to provide informed consent and comply with protocol requirements

Exclusion Criteria:

  • Subjects administered any high energy (>300 KeV) gamma-emitting radioisotope within five (5) physical half-lives prior to Day 1
  • Ongoing treatment with any systemic therapy (e.g. ADT, antiandrogen, GnRH, LHRH agonist or antagonist) for prostate cancer
  • Treatment with ADT in the past 3 months of Day 1
  • Receipt of investigational therapy for prostate cancer within 60 days of Day 1
  • Subjects with any medical condition or other circumstances that, in the opinion of the investigator, compromise the safety or compliance of the subject to produce reliable data or completing the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03739684

Layout table for location information
United States, California
City of Hope National Medical Center
Duarte, California, United States, 91010
Tower Urology
Los Angeles, California, United States, 90048
University of California San Francisco - Helen Diller Cancer Center
San Francisco, California, United States, 94143
Stanford, California, United States, 94305
United States, Connecticut
Yale University
New Haven, Connecticut, United States, 06520
United States, Florida
Moffitt Cancer Center
Tampa, Florida, United States, 33612
United States, Iowa
University of Iowa
Iowa City, Iowa, United States, 52242
United States, Maryland
Johns Hopkins University
Baltimore, Maryland, United States, 21287
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48109
United States, Missouri
Washington University - Mallinckrodt Institute of Radiology
Saint Louis, Missouri, United States, 63110
United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
United States, Wisconsin
University of Wisconsin
Madison, Wisconsin, United States, 53705
Chu de Quebec - Universite Laval
Quebec, Canada, G1R2J6
Sponsors and Collaborators
Progenics Pharmaceuticals, Inc.
Layout table for investigator information
Study Director: Jessica D Jensen Progenics Pharmaceuticals, Inc.
Layout table for additonal information
Responsible Party: Progenics Pharmaceuticals, Inc. Identifier: NCT03739684    
Other Study ID Numbers: PyL 3301
First Posted: November 14, 2018    Key Record Dates
Last Update Posted: April 23, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Progenics Pharmaceuticals, Inc.:
Positron emission tomography
biochemical recurrence
rising PSA
radical prostatectomy
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Prostatic Diseases
Disease Attributes
Pathologic Processes